Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Trial details
- Registry ID
- NCT05611931
- Drugs studied
- Selinexor
TrialRedline tracks 12 clinical trials sponsored by Karyopharm Therapeutics Inc: 4 Phase 3, 1 Phase 2 / 3, 6 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931 | Selinexor | Active not recruiting | 2026-05-22Actual |
| Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389 | Ruxolitinib, Selinexor | Active not recruiting | 2026-02-20Actual |
| Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]NCT03555422 | Selinexor | Completed | 2022-01-22Actual |
| Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaNCT03110562 | Bortezomib, Dexamethasone, Selinexor | Completed | 2020-02-18Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022 | Cisplatin (combination therapy), Dexamethasone (combination therapy), Gemcitabine (combination therapy), Rituximab (combination therapy) and 2 more | Active not recruiting | 2026-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentNCT04256707 | Docetaxel, FOLFIRI, Pembrolizumab, Selinexor 100 mg and 3 more | Completed | 2024-07-31Actual |
Names as written in the registry records.
NCT02227251 · Karyopharm Therapeutics Inc
Before: Estimated. After: Actual.
Before: 244 participants (planned). After: 279 participants (actual).
Before: Estimated. After: Actual.
Before: Dec 2026. After: 2 Jun 2026.
Before: Active not recruiting. After: Terminated.
NCT05611931 · Karyopharm Therapeutics Inc
Before: Estimated. After: Actual.
Before: Aug 2026. After: 22 May 2026.
NCT05611931 · Karyopharm Therapeutics Inc
Before: Estimated. After: Actual.
Before: 276 participants (planned). After: 257 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT02227251 · Karyopharm Therapeutics Inc
Before: Apr 2027. After: Dec 2026.
Before: Recruiting. After: Active not recruiting.
NCT04442022 · Karyopharm Therapeutics Inc
Before: Dec 2025. After: Dec 2026.
Before: Recruiting. After: Active not recruiting.
NCT03555422 · Karyopharm Therapeutics Inc
Before: Active not recruiting. After: Completed.
NCT04562389 · Karyopharm Therapeutics Inc
Before: Estimated. After: Actual.
Before: Mar 2026. After: 20 Feb 2026.
NCT05980806 · Karyopharm Therapeutics Inc
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of Participants with Spleen Volume Reduction 35 (SVR35) at Week 24.. After: Measure: Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24.
Before: 118 participants (planned). After: 58 participants (planned).
Before: Apr 2026. After: Jun 2027.